
MBX Biosciences (NASDAQ:MBX) used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key development milestones across its endocrine and metabolic disease pipeline.
President and CEO Kent Hawryluk said the company is focused on once-weekly canvuparatide and its expanding obesity portfolio, which is built on MBX’s proprietary Precision Endocrine Peptide, or PEP, technology. He said the company has $440 million in cash, which it expects will fund operations into 2029.